Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY209 Phase 1 in Healthy Volunteers
NCT03492398Phase 1Completed
- Sponsor
- Shaperon
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hy209gel in atopic dermatitis (AD) (7 cohorts), sponsored by Shaperon. Primary endpoint: Incidence of Treatment Emergent Adverse Events at Day 38. Started Jan 2018; status: completed.
02
Drugs
hy209gel
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03492398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492398.